Research ArticleClinical Investigation
Open Access
Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
Christine E. Mona, Matthias R. Benz, Firas Hikmat, Tristan R. Grogan, Katharina Lueckerath, Aria Razmaria, Rana Riahi, Roger Slavik, Mark D. Girgis, Giuseppe Carlucci, Kimberly A. Kelly, Samuel W. French, Johannes Czernin, David W. Dawson and Jeremie Calais
Journal of Nuclear Medicine July 2022, 63 (7) 1021-1026; DOI: https://doi.org/10.2967/jnumed.121.262426
Christine E. Mona
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
3Institute of Urologic Oncology, UCLA, Los Angeles, California;
Matthias R. Benz
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
Firas Hikmat
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
Tristan R. Grogan
4Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California;
Katharina Lueckerath
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
3Institute of Urologic Oncology, UCLA, Los Angeles, California;
Aria Razmaria
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
Rana Riahi
5Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California;
Roger Slavik
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
Mark D. Girgis
6Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California; and
Giuseppe Carlucci
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
Kimberly A. Kelly
7Department of Biomedical Engineering, University of Virginia School of Engineering and Applied Sciences, and Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia
Samuel W. French
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
5Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California;
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
3Institute of Urologic Oncology, UCLA, Los Angeles, California;
David W. Dawson
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
5Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California;
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
3Institute of Urologic Oncology, UCLA, Los Angeles, California;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 7
July 1, 2022
Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
Christine E. Mona, Matthias R. Benz, Firas Hikmat, Tristan R. Grogan, Katharina Lueckerath, Aria Razmaria, Rana Riahi, Roger Slavik, Mark D. Girgis, Giuseppe Carlucci, Kimberly A. Kelly, Samuel W. French, Johannes Czernin, David W. Dawson, Jeremie Calais
Journal of Nuclear Medicine Jul 2022, 63 (7) 1021-1026; DOI: 10.2967/jnumed.121.262426
Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
Christine E. Mona, Matthias R. Benz, Firas Hikmat, Tristan R. Grogan, Katharina Lueckerath, Aria Razmaria, Rana Riahi, Roger Slavik, Mark D. Girgis, Giuseppe Carlucci, Kimberly A. Kelly, Samuel W. French, Johannes Czernin, David W. Dawson, Jeremie Calais
Journal of Nuclear Medicine Jul 2022, 63 (7) 1021-1026; DOI: 10.2967/jnumed.121.262426
Jump to section
Related Articles
Cited By...
- Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients
- Expression of fibroblast activation protein-{alpha} in human deep venous thrombus
- Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial
- Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma
- Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake